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1. Introduction 
Glucocorticoids were first introduced in the 1940s and have become a widely prescribed 
class of drugs. Corticosteroids are a class of chemicals that includes steroid hormones 
naturally produced in the adrenal cortex of vertebrates and analogues of these 
hormones that are synthesized in laboratories. Corticosteroids are involved in a wide 
range of physiologic processes, including stress response, immune response, and 
regulation of inflammation, carbohydrate metabolism, protein catabolism, blood 
electrolyte levels, and behavior. They are some of the most common drugs for 
management of patients undergoing stressful situations such as surgery and dentstry 
(Gibson 2004).  
It has thus become common for standard textbooks in dentistry to recommend the 
administration of oral or intravenous steroids in the management of oral lesions.  
Steroids have different effects on different tissues, which are dose dependent. The reason for 
varied effect of steroids lies in its mechanism of action (Grover 2007).  
Glucocorticoids have potent anti-inflammatory actions, including the reduction in the 
number and function of various immune cells, such as T and B lymphocytes, monocytes, 
neutrophils, and eosinophils, at sites of inflammation. Glucocorticoids decrease the 
production of cytokines, chemokines, and eicosanoids and enhances the production of 
macrophage migration inhibitory factor (Gibson 2004).  
Corticosteroid drugs are widely used in oral medicine such as in vesiculobullous diseases, 
orofacial granulomatosis, temporal arteritis and other oral mucosal disorders. Topical 
corticosteroids should be considered the treatment of choice unless the disease is very 
extensive. Systemic therapy is reserved for those with severe, refractory disease.  
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2. Mucosal ulceration and inflammation 
2.1. Recurrent Aphthous Stomatitis 
Recurrent Aphthous Stomatitis (RAS) are among the most common oral lesions in the 
general population, with a frequency of 5–25% and three month recurrence rates as high as 
50%. Aphthous ulcers are often quite painful; may lead to difficulty in speaking, eating, and 
swallowing; and may negatively affect patients’ quality of life (Ship 1996).  
RAS is classified as minor, major, and herpetiform. Minor RAS involves the presence of one 
to five ulcers at a time, with each ulcer less than 1 cm in diameter.  
Major aphthae are a cause of significant dysphagia and often result in extensive scarring. In 
herpetiform RAU there are 10–100 ulcers at a time, ulcer size is usually 1–3 cm, and the 
ulcers form clustersthat coalesce into widespread areas of ulceration lasting 7–10 days (Rees, 
Woo 1996).  
The use of topical and systemic steroids in an attempt to manage apthous stomatitis is based 
on the presumption that the aphthae are the result of a noninfectious inflammatory process. 
Corticosteroids may act directly on T lymphocytes or alter the response of effect or cells to 
precipitants of immunopathogenesis (Vincent 1992).  
2.1.1. Topical corticosteroids 
Topical corticosteroid use in patients with RAS is intended to limit the inflammatory process 
associated with the formation of aphthae.  
There are two double-blind, placebo-controlled trials have evaluated the efficacy of topical 
corticosteroids for RAS (Merchant 1978; Thompson 1989). The patients enrolled in one trial 
had minor RAS. Classification of ulcers was not available for the other trial. Both trials 
assessed patients for immuno -competence through laboratory studies. One trial excluded 
other medications used in RAS (Thompson 1989). In both trials there were significant 
reductions, compared with placebo, in ulcer duration and pain severity and no changes in 
the frequency of RAS in patients who applied betamethasone gel or beclomethasone aerosol 
spray to ulcers four times daily for six days to four weeks (Vincent 1992; Thompson 1989).  
Two non-placebo controlled trials found no significant differences between triamcinolone 
ointment or betamethasone tablets and adhesive vehicles and Orabase in the frequency and 
duration of severe RAS. Subjective improvement tended to be greater with corticosteroids 
than with adhesive vehicle (Orabase), although the difference was not statistically 
significant (MacPhee 1968). A single blind, placebo-controlled trial involving fluocinonide 
ointment was performed in patients with minor and major RAS. Fluocinonide ointment 
significantly reduced ulcer duration, but ulcer frequency and subjective improvement were 
the same as for adhesive vehicle (Orabase). In the latter three trials, study design, ulcer 
severity, and vehicle activity may have contributed to findings inconsistent with those in the 
doubleblind, placebo-controlled studies (Pimlott 1983).  
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The drugs most commonly adopted for local oral application in RAS are hydrocortisone 
hemisuccinate (as pellets of 2. 5 mg) and triamcinolone acetonide (in an adhesive paste 
containing 0. 1% of the steroid). There is little risk of adrenal suppression provided that the 
recommended dose (fourtimes daily) is adhered to (Field 2003).  
In severe RAS may be necessary to use a more potent steroid preparation. High potency 
topical steroid preparation such as fluocinonide, betamethasone or clobetasol placed directly 
on the lesions shortens healing time and reduces the size of lesion. The gel can be carefully 
applied directly to the lesion after meals and at bedtime 2-3 times a day or mixed with an 
adhesive such as orabase prior to application. Recently, Lo Muzio et al. treated oral 
aphthous lesions by applying clobetasol propionate with a bioadhesive system, which 
resulted insurprisingly good outcomes (Lo Muzio 2001).  
Larger lesions can be treated by placing a gauge sponge containing the topical steroid on the 
ulcer and leaving it in place for 15-30 min to allow for longer contact of the medication. 
Ulcerations located in the areas that make them difficult to see or reach can be controlled by 
topical dexamethasone elixir, 0. 5 mg / 5 ml held over the area or applied with a saturated 
gauge pad to the ulcers, four times per day for 15 min (Lo Muzio 2001) and betamethasone 
sodium phosphate rinse (dissolve 0. 5 mg in 5 mL of water and rinse for 2–3 min), steroid 
aerosol (e. g. beclometasone diproprionate, 100 lg/puff) , or a high-potency topical 
corticosteroid, such as clobetasol 0. 05% in orabase or fluocinonide 0. 05% in orabase (Natah 
2004).  
2.1.2. Systemic corticosteroids 
Major apthous ulcers often require systemic treatment as an initial approach. Therapy with 
prednisone 40 mg/day for one week is usually adequate to control the presenting outbreak. 
Systemically, oral prednisone is most commonly employed. Systemic prednisone therapy 
should be started at 1. 0 mg/kg a day as a single dose in patients with severe RAS and 
should be tapered after 1-2 weeks. Intralesional steroids can be used to treat large indolent 
major RAS lesions (Field 2003).  
2.2. Behcet’s disease 
Behcet’s disease is a multisystem, chronic relapsing inflammatory disease of unknown 
cause, which is characterized by recurrent oral (aphthous) ulcers, genital ulcers, uveitis and 
skin lesions. There maybe a variety of other manifestations including joint, central nervous 
system, vascular and intestinal lesions of variable severity (Lai 1995).  
Patients with Behcet’s disease usually have repeated exacerbations and remission of their 
clinical symptoms, and in these individuals treatment is essentially symptomatic. The choice of 
therapy depends on whether the clinical manifestations of the disease are local or systemic.  
Local treatment with corticosteroids often controls oral and genital ulcers, and 
immunosuppressive therapy is reserved for severe cases of mucocutaneous involvement 
(Yazici 1991).  
 
State of the Art of Therapeutic Endocrinology 90 
Immunosuppressive therapy is the mainstay of treatment for Behcet’s disease. Successful 
treatment consists of anti-inflammatory agents that modify neutrophil activity. In the acute 
phase, prednisone, at doses of 40-60 mg/day, may be helpful, used alone or in combination 
with other immunosuppressive agents (Reich 1998).  
Systemic corticosteroids continue to be used extensively, and may be administered as 
intravenous pulse therapy.  
2.3. Oral Lichen Planus (OLP) 
Lichen Planus (LP) is an unique inflammatory disorder that affects the skin, mucous 
membranes, nails and hair was first described and named by Erasmus Wilson in 1869 (Oztas 
2003). The pathogenesis of LP is not entirely understood. It is a disorder of altered cell 
mediated immunity with exogenous antigens targeting the epidermis.  
Various medical therapies are used for the treatment of Phototherapy has been used in the 
treatment of LP for many years. The therapeutic properties of corticosteroids were first 
demonstrated by Edward Kendall and Philip Hench in 1948 (Hench 1949).  
Corticosteroids may be applied topically as ointments, pastes, lozenges or mouthwashes or 
through an inhaler with a special adapter.  
The best treatment for OLP includes the use of high-potency topical corticosteroids 
(Setterfield 2000, Bruce 2007).  
It has been reported that topical corticosteroids, which have fewer side effects, are equally or 
even more effective than systemic corticosteroids (Lodi 2005).  
2.3.1. Topical corticosteroids 
Topical corticosteroids are the main stay in treating mild to moderately symptomatic 
lesions. They are widely used in the treatment of OLP to reduce pain and inflammation. 
Options (presented in terms of decreasing potency) include 0. 05% clobetasol proprionate 
gel, 0. 1-0. 05% betamethasone valerate gel, 0. 05% fluocinonide gel, 0. 05% clobetasol 
ointment or cream and 0. 1% triamcinolone acetonide ointment (Levin 2002).  
Triamcinolone acetonide is commonly used either in orabase or lozenge (Thongprasom 
1992, Zegarelli 1969). A number of investigations have determined the efficacy of 
triamcinolone acetonide 0. 1% suspension in the treatment of OLP. This drug is available 
over the counter and is useful in the treatment of OLP (Rabiyi 2003).  
An aqueous suspension of triamcinolone acetonide 0. 1% was used as an oral rinse in the 
treatment of 46 patients with symptomatic oral lichen planus (Vincent 1990). This method 
proved to be effective, resulting in "complete relief " in 27 patients. Although these results 
most likely refer to improvement in patients' symptoms, no specific information is provided 
regarding the clinical improvement with this therapy.  
Betamethasone valerate, an even more potent anti-inflammatory agent, produced dramatic 
results in a number of controlled studies in patients with oral lichen planus. In a double-
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blind study, Cawson treated 30 patients with symptomatic oral lichen planus with 
betamethasone (0.1 mg) pellets. In 8 patients, all lesions virtually disappeared within 1 
month, and during the same period, 20 of 30 patients showed substantial improvement. 
Only two patients failed to respond to this therapy (Cawson 1968).  
Similarly, Tyldesley and Harding showed betamethasone valerate aerosol fitted with a 
special intraoral adaptor was an excellent treatment in the majority of 23 patients tested in a 
double-blind study (Tyldesley 1977). Greenspan et al. confirmed the efficacy of both 
betamethasone valerate aerosol and pellets in a double-blind study, noting improvement in 
17 of 19 patients (Greenspan 1978).  
High-potency steroid mouthwashes such as disodium betamethasone phosphate or 
clobetasol propionate, can be used in widespread oral LP but these may cause a significative 
systemic absorption leading to a pituitary- adrenal axis suppression (Gonzalez-Moles 2002).  
Fluocinolone is another steroid, which has been used for treatment of OLP. Compared with 
the placebo, this drug has been found to be more effective (Voute 1993).  
Recently, fluticasone propionate spray has been used effectively in the short-term 
management of symptomatic OLP, but 10% of the patients did not tolerate such treatment 
for more than 3 weeks (Hegarty 2002). The more potent fluorinated steroids can be very 
effective and include fluocinonide 0. 05% (Silverman 1991; Lozada 1980) and fluocinolone 
acetonide 0. 1%. (Thongprasom 1992) Fluocinonide 0. 05% and fluocinolone acetonide 0. 1% 
have been found to be effective in the treatment of severe oral LP that has failed to respond 
to other medications (Thongprasom 1992; Voute 1993).  
A study evaluated fluocinolone acetonide 0. 1% in three groups: solution (FAS), Orabase 
(FAO), and both. The best results achieved with FAO (complete remission of 77. 3% of 
patients). This study had a long-term follow-up, without having a control group 
(Thongprasom 2003).  
A study confirmed the efficacy of topical fluocinolone acetonide gel 0. 025 %, along with the 
topical antimicrobial drug chlorhexidine, in treatment of erosive OLP (Thongprasom 2003).  
Another study showed no difference between the fluticasone propionate (FP) spray and 
betamethasone sodium phosphate (BSP) mouth rinse. But FP was found to be more acceptable 
to patients than BSP, because of the convenience of the spray form (Hegarty 2002).  
The application of fluocinonide ointment (0. 05%) compounded with orabase 6 times per 
day or clobetasol propionate ointment (0. 05%) with orabase 3 times per day can control 
erosive lichen planus effectively in most patients (Edwards 2002).  
Fluocinolone acetonide 0. 1% in orabase has been shown to be more effective than a similar 
triamcinolone acetonide 0. 1% preparation with no serious side effects (Thongprasom 1992).  
Clobetasol propionate in aqueous solution, ointment, or orabase has also been shown to be 
effective in OLP. Clobetasol can be more effective than fluocinonide in improving lesions 
and the long-term use of clobetasol (6 months) may help to control the disease, offering 
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substantial disease-free periods in 65% of the patients after 6 months of follow-up 
(Carbone1999).  
Clobetasol propionate, a very potent corticosteroid in the Miller and Munro classification, 
was used in a 4% hydroxy ethylcellulose bioadhesive gel (Carbone1997). Clobetasol 
propionate 0. 05% ointment has been shown to heal OLP, but this study had a small sample 
group, without any control group or follow-up (Roed-Petersen 1992). Among the three 
preparations of clobetasol propionate 0. 05% (ointment, Orabase, and the adhesive denture 
paste) the best results have been achieved with clobetasol propionate in an adhesive denture 
paste (Lo Muzio 2001).  
Although there are some reports of systemic absorption and adrenal suppression from 
super-potent topical steroids in the treatment of chronic skin disorders‚ adrenal suppression 
has not been found in long-term oral application of topical corticosteroids such as 
fluocinonide 0. 05%, fluocinolone acetonide 0. 1%, and clobetasol 0. 05% (Carbone1999).  
Acute pseudomembranous candidiasis is the only common side effect from topical 
corticosteroid therapy (Thongprasom 1992). This can be prevented with antifungal 
(miconazole gel) alone or with chlorhexidine mouthwashes (Carbone1999).  
2.3.2. Intralesional corticosteroids 
Intralesional injection of corticosteroid for recalcitrant or extensive lesions involves the 
subcutaneous injection of 0. 2–0. 4 mL of a 10 mg/mL solution of triamcinolone acetonide by 
means of a 1. 0-mL 23 or 25 gauge tuberculin syringe (Edwards 2002).  
Intralesional injections of hydrocortisone, dexamethasone, triamcinolone acetonide and 
methylprednisolone have been used in the treatment of OLP (Zegarelli 1980). However, the 
injections can be painful, are not invariably effective, and have a localized effect such as 
mucosal atrophy. Three to four or twice weekly treatments of intralesional triamcinolone 
acetonide in doses of 0. 5–1 ml of a 1-mg/ml suspension seem to be a practical supplement 
for the treatment of erosions (Edwards 2002).  
Zegarelli combined the use of topical and weekly intralesional corticosteroids in seven 
patients. After 3 weeks, five patients were graded as having 100% clinical improvement. 
Furthermore, in most cases, a remission of several months was noted; recurrences were 
milder than the original disease state and were managed with topical agents alone (Zegarelli 
1983). It is unclear why the response to topical corticosteroid therapy is so variable. 
Undoubtedly, the frequency of application of topical corticosteroids makes compliance 
difficult because optimal effects are not achieved unless they are applied between five and 
ten times daily (Zegarelli 1980).  
2.3.3. Systemic corticosteroids 
Systemic corticosteroids are reserved for recalcitrant erosive or erythematous LP where 
topical approaches have failed. Systemic prednisolone is the drug of choice, but should be 
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used at the lowest possible dosage for the shortest duration (40-80 mg for 5-7 days) (Eisen 
2005).  
Systemic prednisone can be used to control the ulcers and erythema in OLP. Systemic 
corticosteroids may be indicated in patients whose condition is unresponsive to topical 
steroids or in patients with mucocutaneous disease and in high doses (1. 5-2 mg/kg/daily), 
but adverse effects are possible even with short courses (Zegarelli 1980; Chainani-Wu 2001).  
The oral dose of prednisone for a 70-kg adult ranges from 10–20 mg/day for moderately 
severe cases to as high as 35 mg/day (0. 5 mg/kg daily) for severe cases (Zegarelli 1983). 
Prednisone should be taken as a single morning dose to reduce the potential for insomnia 
and should be taken with food to avoid nausea and peptic ulceration. Significant response 
should be observed within one to 2 weeks.  
When systemic corticosteroids are prescribed for periods of longer than 2 weeks, the dosage 
of steroid must be gradually tapered to avoid precipitating an adrenal crisis. Tapering can 
be accomplished by decreasing the daily dose of prednisone by 5 mg per week (Edwards 
2002).  
Some studies have compared the efficacy of corticosteroids with some other drugs. For 
example in a double-blind randomized controlled study, compared the efficacy of topical 
zinc sulfate in combination with 0. 05% fluocinolone ointment in the treatment of OLP after 
2 weeks of treatment, was founded that topical zinc sulfate in combination with 0. 05% 
fluocinolone ointment reduced the severity erosive OLP better than 0. 05% fluocinolone 
separately (Mehdipour & Taghavi 2010).  
2.4. Erythema Multiforme (EM) 
Erythema Multiforme is a skin condition considered to be hypersensitivity reaction to 
infections or drugs. It consists of a polymorphous eruption of macules, papules, and 
characteristic ‘target’ lesions that are symmetrically distributed with a propensity for the 
distal extremities. There is minimal mucosal involvement. Herpes simplex virus (HSV) is the 
most commonly identified etiology of this hypersensitivity reaction, accounting for more 
than 50 percent of cases. Although EM was first clinically recognized in the early 19th 
century and referred to by a variety of names, it was not until 1860 that Ferdin and von 
Hebra termed the disease “Erythema Multiforme (Forman 2002).  
Erythema multiforme (EM) was once thought to be the early presentation of a continuum of 
diseases related to Stevens-Johnson syndrome (SJS), with toxic epidermal necrolysis (TEN) 
believed to be a distinct entity. It is now generally accepted that a separation exists between 
EM and SJS. Currently, two different classifications exist: first, an erythema multiforme 
spectrum (minor and major) and second, an SJS and TEN spectrum (Lamoreux 2006; French 
2008).  
SJS and its more severe progression, TEN, are both rare mucocutaneous diseases that can be 
life-threatening and almost always caused by drugs (49). SJS was first described in 1922 by 
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two physicians, Stevens and Johnson, who described a skin eruption similar to EM that also 
included purulent conjunctivitis, stomatitis,, and fever (Forman 2002).  
Management of erythema multiforme involves determining the etiology when possible. The 
first step is to treat the suspected infectious disease or to discontinue the causal drug.  
2.4.1. Topical steroid therapy 
Mild cases of Erythema Multiforme do not require treatment. Oral topical steroids may be 
used to provide symptom relief (Shin 2001).  
Lozada-Nur and Zhong Huang reported that an adhesive paste (Orabase) form of clobetasol 
propionate, the most potent topical corticosteroidis a safe and efficacious alternative to 
systemic therapy in erosive oral lesions (Lozada-Nur F 1994).  
Mouthwashes of clobetasol propionate in aqueous solution may offer an alternative topical 
approach to this patient population. The mouthwash solution provides ready access to all 
lesional areas, and there is excellent control over the contact time between drug and lesion 
(Jacobson 1986).  
2.4.2. Systemic steroid therapy 
The role of systemic corticosteroids in Erythema Multiforme Major (EMM) and SJS is 
controversial. There is no literature to date based on a large, prospective, randomized, or 
double-blind study evaluating use of systemic corticosteroids in EMM/SJS.  
Moderate to severe oral Erythema Multiforme may be treated with a short course of 
systemic glucocorticosteroid in patients without significant contraindications to their use. 
Prednisone may be used in patients with many lesions at dosages of 40 to 80 mg per day for 
one to two weeks then tapered rapidly (Lamoreux 2006). There have been no controlled 
studies of prednisone’s effectiveness, and its use in patients with herpes-associated 
Erythema Multiforme may lower the patient’s resistance to HSV and promote recurrent 
HSV infection followed by recurrent Erythema Multiforme (Volcheck 2004).  
The dosing and route of administration that provides the most benefit for EMM and SJS 
patients is in question. Early therapy with systemic prednisone (0. 5 to 1. 0mg/kg/day) or 
pulse methylprednisolone (1mg/kg/day for 3 days) has been shown to be effective (Scully 
2008). One author suggests tapering the oral prednisolone over 7 to 10 days, while Patterson 
et al. suggests a high dose of corticosteroids for EMM patients followed by a four-week 
tapering course (Chrousos 2004). Still another suggests a bolus infusion for 3 to 7 days of 
coricosteroids, which showed no relapses after treatment was discontinued (Kakourou1997). 
Intravenous (IV) pulsed dose methylprednisolone (3 consecutive daily infusions of 20–
30mg/kg to a maximum of 500 mg given over 2 to 3 hours) has also been reported, with the 
suggestion that this approach is superior to oral prednisone because the greatest benefit is 
seen when treatment is administered as early as possible in the progression of the cutaneous 
insult (Martinez 2000).  
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Kardaun and Jonkman recently proposed dexamethasone pulse therapy (1. 5mg/kg IV over 
30 to 60 minutes on 3 consecutive days) to avoid long-term use of systemic corticosteroids 
(Kardaun 2007). The authors described the pleomorphic effects of dexamethasone on the 
immune system, including inhibition of epidermal apoptosis by several mechanisms. These 
mechanisms include suppression of various cytokines, such as TNF-alpha; inhibition of 
interferon-gamma-induced apoptosis; and inhibition of Fas-mediated keratinocyte apoptosis 
(Yeung 2005).  
When treating TEN, it is generally agreed that after widespread sloughing occurs, any risk 
of infection outweighs the potential benefits of systemic corticosteroid therapy (Wolverton 
2007).  
Recurrent Erythema Multiforme often is secondary to HSV-1 and -2 reactivation, although 
the HSV may be clinically silent (Huff 1992).  
2.5. Pemphigus 
Pemphigus refers to a group of rare chronic mucocutaneous diseases characterized by 
painful lesions caused by intraepidermal antholytic structures in the skin and mucous 
membrane (Sirois 2000).  
Oral mucosal lesions in Pemphigus are common (50%-70%) and predominantly appear as 
buccal erosions in the occlusal line, which is most exposed to trauma and also on the palate, 
gingival and tongue (Sirois 2000).  
The exact nature of the disease remains unknown. Pemphigus is characterized by intra-
epithelial bulla formation, due to autoantibodies directed against proteins of the 
desmosome-tonofilament complex between keratinocytes (Sirois 2000).  
Pemphigus vulgaris (PV) has a high morbidity and mortality rate without treatment. 
Because of the rarity of the disease, there is not yet a standard treatment regimen (Cotell 
2000).  
The aim of treatment in pemphigus vulgaris is the same as in other autoimmune bullous 
diseases, which is to decrease blister formation, promote healing of blisters and erosions, 
and determine the minimal dose of medication necessary to control the disease process 
(Knudson 2010).  
Until now, treatment consists mostly of the use of corticosteroid and immunosuppressive 
drugs. The use of corticosteroids in the 1950s had reduced mortality from 60% to 90% to 
about 30%. The current mortality was about 6. 2% (range 0 to 10%) and did not show further 
significant reduction (Bystryn 1996).  
The treatment depends on the prognostic elements of the condition, such as the extent of the 
lesions and antibody levels. Treatment is administered in 2 phases: a loading phase, to 
control the disease, and a maintenance phase, which is further divided into consolidation 
and treatment tapering. The basic treatment for pemphigus consists of either local or 
systemic corticosteroid therapy (Fellner 2001).  
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2.5.1. Topical corticosteroids 
Local corticosteroid therapy is used in cases where the PV is not extensive and lesions are 
limited to the oral cavity. Corticosteroids can be prescribed in the form of a paste, an 
ointment or a mouthwash administered as monotherapy or as adjunctive therapy with a 
systemic treatment (Fellner; Ruocco 2001).  
In patients with no progressing oral lesions, moderate to high potency topical 
corticosteroids are recommended, applied 2-3 times a day, such as 0. 05% fluocinolone 
acetonide or 0. 05% clobetasol propionate (Hashimoto; Prajapati 2008).  
Dumas et al. described 7 pemphigus patients, 3 of whom were treated with clobetasol 
propionate 0. 05% cream as monotherapy for their mild PV. PV was defined as “mild” if 
fewer than 10 new bullae appeared per week and if the circulating pemphigus antibody titer 
was 1:320. The cream was applied twice a day for at least 15 days, and then tapered. Lesions 
were controlled in only 1 of the 3 PV patients (Dumas 1999).  
2.5.2. Systemic corticosteroid therapy 
In patients with severe disease and spreading of the lesions to skin surfaces, systemic 
corticosteroids are the treatment of choice (Knudson 2010).  
The dosing schedule of systemic corticosteroids in pemphigus is largely empirical (Ratnam 
1990). Prednisolone was the first drug used to treat this disease and almost in all situations, 
is the first line of treatment (Camisa 1998).  
The starting dose is high; a total oral dose of 100–200 mg Prednison is administered daily until 
subsidence of clinical signs. This dose can gradually be decreased to a maintenance level of 40 to 
50 mg daily. Topical application of corticoids is effective if small, isolated areas of the oral 
mucosa are involved. The acute phase of pemphigus is associated with changes in gastric mucosa 
and this condition is further aggravated by ingestion of corticosteroids (Fassmann 2003).  
Corticosteroids taken by mouth have many long-term harmful effects, including adrenal 
atrophy, abnormal sensitivity to infection, high blood pressure, hypertriglyceridemia, 
hyperglycemia, cortisone myopathy, erosive duodenitis and stress fracture, as in the case 
presented here. To minimize iatrogenic effects, Lever and Schaumburg recommended a 
treatment called the “high Lever scheme” with very high loading doses (100–175 mg taken 
twice daily for 5–10 weeks) , followed by the “low Lever scheme,” which includes a rapid 
reduction in dosage over a few weeks, with a maintenance dose of 40 mg every 2 days 
accompanied by local adjuvant treatment (Lever 1984).  
The British Association of Dermatologists recommends patients with mild disease to receive 
an initial prednisolone dose of 40-60 mg daily and in more severe cases, 60-100 mg daily. If 
there is no response within a week, the dose is increased by 50-100% until disease control. 
There is no unitized handling considering the tapering of corticosteroids. A 25% dose 
reduction may be performed biweekly with slower decrease after a dose of 20 mg/day has 
been reached (Harman 2003).  
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Two prospective controlled trials explored the effect of i. v. corticosteroid pulses in addition 
to oral prednisolone but did not observe statistical differences between treatment groups 
(Femiano 2002; Mentink 2006).  
In one controlled trial, patients randomized to treatment with either low-dose oral 
prednisolone (45-60mg/day) or high-dose oral prednisolone (120-150mg/day) showed no 
significant difference in the time to achieve remission and in relapse rates at 5 years (Ratnam 
1990).  
A nonrandomized retrospective controlled trial of 71 pemphigus patients assigned 
participants to cohorts receiving prednisone 1 mg/kg/day or 2 mg/kg/day. No statistical 
difference was observed between cohorts in terms of response to treatment; however, 
there was a significantly higher frequency of adverse events, particularly infection, in the 
2 mg/kg/day cohort. Despite the retrospective, nonrandomized nature of the study, the 
results indicate that higher doses of corticosteroid are no more effective than lower doses, 
and are associated with higher rates of complications. Overall, the limited evidence 
indicates that lower steroid dose regimens (=1 mg/kg/day) have equivalent efficacy in 
controlling disease as higher dose regimens, and may have decreased associated 
morbidity (Fernandes 2001).  
Another nonrandomized, controlled trial of 20 PV patients studied participants receiving 
either a 125 mg/day tapering schedule of prednisone or a 50 mg/day tapering schedule of 
prednisone plus intravenous betamethasone 20 mg/day. In this study, the cohort receiving 
the pulse therapy was found to have faster clinical resolution of symptoms, with statistically 
significant difference (Femiano 2002).  
Pulse corticosteroid usually seems to result only in short-term relief from the disease and 
most likely needs continued administration of oral corticosteroids (Funauchi 1997).  
Werth has compared these two therapeutic protocols. It was only a retrospective study that 
included two heterogeneous groups of patients with completely different therapeutic 
regimens for each patient. It included nine patients who had received pulse therapy and six 
patients who had received conventional treatment. Some received only one course of pulse 
therapy, while others received two courses. This study showed the superiority of pulse 
therapy over conventional treatment (Werth 1996).  
2.5.3. Intralesional corticosteroid therapy 
Intralesional corticosteroid therapy accelerates the scarring process of a lesion or is used to 
treat persistent lesions. This treatment, which gives inconsistent results, involves sublesional 
injections given every 7 to 15 days; treatment is stopped after 3 injections if there is no 
improvement. Scarring is accompanied by cutaneous or mucosal atrophy the major 
drawback of this treatment (Fellner; Ruocco 2001). If the patient has extraoral lesions or if 
the oral damage is extensive, systemic corticosteroid therapy is initiated immediately. The 
initial dose depends on the chronicity of the lesions and the severity of the disease. A daily 
application of prednisone 0. 5–2 mg/kg is recommended (Fellner; Toth 2001). Depending on 
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the response, the dose is gradually decreased to the minimum therapeutic dose, taken once 
a day in the morning to minimize side effects.  
The lack of randomized controlled trials precludes any conclusions as to whether these 
protocols are superior to those using higher loading doses. An adjuvant drug is prescribed 
for most patients with severe PV, with the objectives of reducing the cortisone dose and 
ensuring stable remission. However, the use of adjuvant therapy remains controversial 
(Mutasim 2004).  
2.6. Mucous Membrane Pemphigoid (MMP) 
Mucous Membrane Pemphigoid (MMP) or Cicatricial pemphigoid is a rare autoimmune 
blistering disorder that affects the mucous membranes and skin. It was first described by 
Thost in 1911 (Thost 1911).  
This disease is extremely difficult to treat despite the use of aggressive combination 
immunosuppressive regimens. Cicatricial pemphigoid with multiple mucosal site 
involvement has the worst prognosis due to its high resistance to medical therapy resulting 
in loss of function through scarring (Tht Yu 2007).  
During the past 50 years, the mainstay of treatment for MMP has been systemic 
glucocorticoids. However, the high doses needed to obtain clinical response are generally 
poorly tolerated, especially in young patients, and are associated with many adverse effects 
(Borradori 2004).  
2.6.1. Topical steroid therapy 
Mild localized lesions usually respond to topical steroids, including triamcinolone, 
fluocinonide and clobetasol propionate. Patients with mild oral disease should be treated 
with topical and intralesional steroids.  
Desquamative gingivitis can often be managed with topical steroids in soft dental splint that 
covers the gingiva, although the clinician using topical steroids over large areas of mucosa 
must closely monitor the patient for side effects such as candidiasis and effects of systemic 
absorption (Reich 1998).  
Lozada -Nur and Zhong Huang treated patients with severe erosive disease, using 
clobetasol propionate mixed in an adhesive paste. They reported a complete response in 62. 
5% of the series (15 patients), an excellent response in 29. 7% (7 patients), and a failed 
response in 8. 3% (2 patients). They concluded that their treatment was efficacious and safe 
(Lozada-Nur 1991).  
In low risk patients with lesions confined to the oral mucosa and/or skin, topical 
corticosteroids are advised, such as 0. 1% triamcinolone acetonide, 0. 05% 
fluocinoloneacetonide, or 0. 05% clobetasol propionate in orabase, applied 3-4 times a day 
during 9-24 weeks. In patients with isolated erosions, intralesional corticosteroid injections 
(triamcinolone in 5-10 mg/ml solution) can be used. In subjects presenting gingival lesions in 
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the form of desquamative gingivitis, 0. 05% clobetasol propionate is recommended, with 
nystatin 100,000 IU to avoid candidiasis overinfection (Bagan 2005, Scully 2008). When MMP 
affects the palate, esophagus or nasal mucosa, beclomethasone dipropionate or budesonide 
(50-200 μg) can be prescribed (Bagan 2005).  
2.6.2. Systemic steroid therapy 
MMP can be rapidly progressive, and systemic steroids have been used as initial treatment 
for patients with extensive oral ulceration or as additional treatment on patients who did 
not respond to topical steroids. Systemic corticosteroids such as prednisolone at 1- 2 
mg/kg/day are the first-line medications in CP because of their potent anti-inflammatory 
and immunosuppressive effects (Mondino 1981).  
The serum autoantibody titers remain very high after the disappearance of clinical lesions. 
Therefore the benefit of steroids in benign mucous membrane pemphigoid might be due to 
anti-inflammatory actions, including lowered enzyme release, reduced cell migration and 
decreased leakage of humoral factors (Knudson 2010).  
In high risk patients with multiple oral lesions, rapidly progressing spread of the disease to 
other mucosal membranes such as the eyes, genital, esophagus or nasopharyngeal zone, or 
recurrent lesions, the administration of prednisone 1-2 mg/kg/day, with gradual dose 
reduction, and immune suppressors such as cyclophosphamide (0. 5-2 mg/kg/day) , 
azathioprine 1-2 mg/ kg/day, or mycophenolate mofetil 2-2. 5 g/day has been described 
(Bagan 2005; Knudson 2010).  
2.7. Bullous Pemphigoid (BP) 
Bullous Pemphigoid (BP) is an autoimmune disease characterized by subepidermal 
blistering , which are often pruritic (Fitzpatrick 2008).  
Bullous pemphigoid occurs most commonly in the elderly, with an onset between 65 and 75 
years of age. Prognosis is influenced by age and general condition of the patient, not by 
extent of disease activity.  
Treatment includes topical and systemic corticosteroids, steroid-sparing 
immunosuppressants, and tetracycline in combination with niacinamide (Joly 2005).  
2.7.1. Topical steroid therapy 
In a study of 10 patients with extensive and generalized BP, treatment with 0. 05% clobetasol 
propionate cream achieved complete healing in all patients within 17 days of treatment. 
Seven of the 10 patients remained in remission at the time of reporting (1–10 months) 
(Westerhof 1989).  
Twenty patients with BP (involvement of less than 60% body surface) in a second study 
were treated with very potent topical corticosteroids: in seven patients BP was completely 
suppressed and the same number obtained remission with an 11-month follow-up. There 
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were mild side-effects of cutaneous infection and skin atrophy. The use of topical 
corticosteroids has also been reported in a large number of case reports and smaller series of 
fewer than five patients (Zimmermann 1999).  
Potent topical corticosteroids should be considered in patients with limited or moderate 
disease (Mutasim 2004).  
In a large randomized controlled trial, initial disease control and 1-year survival were 
significantly better when treating extensive BP with clobetasol propionate cream 40 mg 
daily compared with oral prednisolone 1mg/kg/day while in moderate BP (< 10 blisters/day) 
outcomes using clobetasol cream and prednisolone 0. 5mg/kg were similar (Joly 2002).  
Recently, lower doses of topical clobetasol propionate (10-30g daily) were shown to have 
similar short-term efficacy but reduced side-effects compared to the high dose topical 
regimen (40g daily clobetasol propionate) (Joly 2009).  
2.7.2. Systemic steroid therapy 
High-doses of systemic corticosteroids are the standard for initial treatment of BP to gain 
control over the eruptions, and prolonged high-doses are often used in severe cases. 
Adverse side effects from systemic corticosteroids seem to be the main cause of mortality in 
BP (Mamelak 2007).  
Recommended initial doses of prednisolone are 20 mg/day or 0. 3 mg/kg/day in localised or 
mild disease, 40 mg/day or 0. 6 mg/kg/day in moderate disease, and 50-70 mg or 0. 75-1 
mg/kg/day in severe disease (Wojnarowska 2002).  
In patients with limited disease, clobetasol propionate cream alone is used; in patients with 
moderate disease, clobetasol propionate cream is combined with dapsone (1. 0-1. 
5mg/kg/day) and in severe cases, oral prednisolone (0. 5mg/kg/day) is added. Instead of 
dapsone, doxycycline (200mg/day) may be given (Kasperkiewicz 2009).  
2.7.3. Intralesional corticosteroid therapy 
Intralesional triamcinolone acetonide 3-10 mg per ml can be administered to resistant 
lesions. Experience in injecting correctly is necessary to maximise efficacy and minimise 
atrophy. Where pemphigoid does not respond to steroids, or large maintenance doses are 
required, other ‘steroid-sparing’ agents can be used. However, the evidence for effectiveness 
of these drugs is limited and many have worrying side effect profiles. They should therefore 
be used cautiously by those with experience in their actions (Reich 1998).  
2.8. Systemic Lupus Erythematosus 
Lupus Erythematosus may run in one of the two well recognized forms. Systemic (acute) or 
Discoid (chronic). Both of them may have oral manifestations. Discoid Lupus 
Erythematosus (DLE) is a chronic skin condition of sores with inflammation and scarring 
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favoring the face, ears and scalp. It probably occurs in genetically predisposed individuals 
(Khare 2011).  
Systemic Lupus Erythematosus (SLE) is a chronic disease characterized by protean 
manifestations, often with a waxing and waning course. In the past, a diagnosis of SLE often 
implied a decreased life span caused by internal organ system involvement or the toxic 
effects of therapy, but recent improvements in care have dramatically enhanced the survival 
of SLE patients. Nonetheless, increased mortality remains a major concern and current 
treatments for SLE remain inadequate (Ippolito 2008).  
Oral ulcerations of systemic lupus erythematosus are transient, occurring with acute lupus 
flares. Symptomatic lesions can be treated with high potency topical corticoids or 
intralesional steroid injections. Systemically low dose prednisone 10-20 mg /day or an 
alternate day dose of 20-40 mg may be needed (Pedersen 1984; Reich 1998).  
Reducing corticosteroid use is an important goal in treatment of patients with SLE if it 
occurs in the context of a treatment that effectively controls disease activity. Therefore, for a 
medical product to be labeled as reducing corticosteroid usage, it should also demonstrate 
another clinical benefit, such as reduction in disease activity as the primary endpoint.  
The evaluation of efficacy should be based on the proportion of patients in treatment and 
control groups that achieve a reduction in steroid dose to less than or equal to 10 mg per day 
of prednisone or equivalent, with quiescent disease and no flares for at least 3 consecutive 
months during a 1-year clinical trial. For a result to be clinically meaningful, the patient 
population should be on moderate to high doses of steroids at baseline. Trials should also 
assess the occurrence of clinically significant steroid toxicities (Ad Hoc Working Group on 
Steroid-Sparing Criteria in Lupus 2004).  
In the localized variety of Discoid Lupus the lesions tend to be confined to the head and 
neck and in the generalized variety they occur both above and below the neck. The disease 
may occur at any age; with higher incidence between 20 to 40 years of age. It has a 
prolonged course and can have a considerable effect on quality of life. Potent topical 
steroids and antimalarials are the mainstay of treatment (Khare 2011).  
Topical steroids are the mainstay of treatment of DLE. Patients usually start with a potent 
topical steroid (e. g., betamethasone or clobetasol) applied twice a day, then switch to a 
lower-potency steroid as soon as possible. The minimal use of steroids reduces the 
recognized side effects like atrophy, telengiaectasiae, striae, and purpura.  
Intralesional injection of corticosteroids (typically, this author uses triamcinolone acetonide 
3 mg/mL) is useful as adjunctive therapy for individual lesions. Potential for atrophy relates 
to the amount of corticosteroid injected in any area; therefore, dilute concentrations are 
preferred. In addition, the treating physician must take care to limit the total dose of the 
injections at any given office/clinic visit to avoid systemic toxicity from the steroids; eg, if a 
patient is given 10 mL of triamcinolone 3 mg/mL, this means that the patient has received a 
total of 30 mg, and toxicity is the same as if it had been delivered orally or by intramuscular 
injection (Panjwani 2009).  
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Oral steroids may be required for the control of systemic lupus but are not generally 
beneficial in DLE. For patients with progressive or disseminated disease or in those with 
localized disease that does not respond to topical measures, the addition of systemic agents 
should be considered.  
3. Facial pain 
3.1. Bell’s palsy 
Idiopathic facial palsy, also called Bell’s palsy, is an acute disorder of the facial nerve, which 
may begin with symptoms of pain in the mastoid region and produce full or partial paralys 
is of movement of one side of the face (Valença 2001).  
Facial nerve paralysis may be congenital or neoplastic or may result from infection, trauma, 
toxic exposures, or iatrogenic causes. Increasing evidence suggests that the main cause of 
Bell’s palsy is reactivation of latent herpes simplex virus type 1 in the cranial nerve ganglia. 
How the virus damages the facial nerve is uncertain (Gilden 2004).  
Treatment of Bell palsy should be conservative and guided by the severity and probable 
prognosis in each particular case. Studies have shown the benefit of high-dose 
corticosteroids for acute Bell palsy (Sullivan 2007; Engström 2008).  
Taverner in 1954 was the first to design a controlled treatment trial of steroids but 
unfortunately the number of patients was too small to permit a signifcant statistical 
evaluation (Taverner 1954).  
Attempts to treat Bell’s palsy with steroids changed in the 1970s. After the initial publication 
of Adour et al. several series of treatments with prednisone for Bell’spalsy were designed, 
but almost all of them were of unsatisfactory quality (Adour 1972). Nevertheless, the 
majority of authors claimed that they had shown steroids to be benefcial to a statistically 
signifcant degree.  
Two recent systematic reviews concluded that Bell's palsy could be effectively treated with 
corticosteroids in the first seven days, providing up to a further 17% of patients with a good 
outcome in addition to the 80% that spontaneously improve (Ramsey 2000; Grogan 2001).  
Other studies have shown the benefits of treatment with steroids; in one, patients with 
severe facial palsy showed a significant improvement after treatment within 24 hours 
(Shafshak 1994; Williamson 1996).  
Immunocompetent patients without specific contraindications are prescribed prednisone at 
1 mg/kg/d (maximum 80 mg) for the first week, which is tapered over the second week. 
Around a fifth of patients will progress from partial palsy, so these patients should also be 
treated (Ramsey 2000).  
However the Sullivan study with 496 participants compared different combinations of 
prednisolone, acyclovir and placebo. They found significant benefit from prednisolone but 
not acyclovir (Sullivan 2007).  
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Hato assessed the efficacy of valacyclovir with 296 participants divided into two groups 
(valacyclovir with prednisolone,and placebowith prednisolone) and found significant 
benefit from valacyclovir (Hato 2007).  
3.2. Ramsay Hunt syndrome 
Ramsay Hunt syndrome (RHS) is caused by the reactivation of a previous Varicella zoster 
virus (VZV) infection. RHS is a potentially serious viral infection that accounts for 
approximately 12% of all facial nerve palsies (Robillard 1986; Uri 2003).  
VZV is also the cause of “shingles,” which frequently presents with a classic painful 
dermatomal distribution of vesicles and crusted skin ulcerations. In addition to the alarming 
facial palsy, RHS may also be characterized by severe otalgia, sensorineural hearing loss, 
vertigo, painful skin vesicles and aguesia in the ipsilateral anterior tongue (Hiroshige 2002).  
The treatment of Ramsay Hunt syndrome is not entirely agreed upon. Definitive treatment 
consists of antiviral therapy and sometimes includes steroids. Adjunctive steroid therapy 
can be helpful in the management of the facial paralysis of RHS (Kinishi 2001).  
However, many authors caution against implementing steroid therapy, especially with 
periocular lesions, as they fear dissemination of the VZV infection (Van de Steene 2004; 
Hyvernat; Hill 2005).  
The largest retrospective treatment study showed a statistically significant improvement in 
patients treated with acyclovir and prednisone within 3 days of onset. Complete recovery 
occurred in 75% of patients treated within the first 3 days, but in only 30% of those treated 
after 7 days. This suggests that prompt diagnosis and management improves outcome in 
Ramsay Hunt syndrome. Importantly, no statistically significant outcome differences were 
noted between patients treated with intravenous or oral acyclovir (Murakami 1997).  
A large prospective study demonstrated that combination therapy with acyclovir and 
steroids led to better recovery of facial nerve function than steroids alone (Kinishi 2001). 
These findings were confirmed by responses to nerve excitability testing. Although there are 
no evidence-based dosing recommendations, published trials typically administered 
acyclovir at 800 mg by mouth 5 times/day for 7-10 days and prednisone at 1 mg/kg/day by 
mouth for 5 days followed by a taper (Murakami 1997).  
RHS may present with a spectrum of clinical variations, including facial swellings that 
appear to be of odontogenic origin. As a result, dentists may be challenged to make the 
correct diagnosis of RHS versus an odontogenic infection in a timely manner. Appropriate 
supportive and prompt antiviral therapy combined with close follow-up is associated with 
significantly better functional recovery and outcomes (Kinishi 2001).  
3.3. Postherpetic Neuralgia (PHN) 
Postherpetic Neuralgia (PHN) continues to be a significant clinical problem, with an average 
of 25% of patients developing persistent neuropathic pain after acute herpes zoster (HZ) 
(Pavan-Langston; Schmader 2008).  
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This condition signals damage to the affected nerve. Patients may continue experiencing 
pain and discomfort even after blisters have already cleared. Usually, patients may feel a 
sharp or deep pain along the area were blisters first appeared. It is believed that repetitive 
painful stimuli that reach the central nervous system might lead to central sensitization of 
the nociceptive system, the most important mechanism underlying long-lasting chronic 
pain. Interventions that decrease the repetitive painful stimuli and inflammation during the 
acute phase of HZ may attenuate central sensitization and substantially reduce the incidence 
of chronic pain (Kelly 2001; Johnson 2002).  
Treatment includes corticosteroids, which are used to treat pain, swelling and effectively 
reduces the risk of recurrence of post-herpetic neuralgia. Steroids were found to accelerate 
the resolution of acute neuritis and provide a clear improvement in quality-of-life measures 
in comparison to those patients treated with antivirals alone. The use of oral steroids had no 
effect on the development or duration of postherpetic neuralgia (Dworkin 2007).  
Historically, epidural, intrathecal, and sympathetic nerve blocks have all been used in the 
treatment of pain caused by HZ and PHN. It was accepted by some investigators that nerve 
blocks do not provide lasting relief in established PHN, but injection of corticosteroids has 
been suggested to be of some benefit.  
Prednisolone, a corticosteroid, is the most common drug administered in heavy doses to 
herpes patients. Moderate doses of prednisone 40 mg daily for 10 days, which is gradually 
tailed off over the following 3 weeks is an effective and safe regime which reduces the 
occurrence of postherpetic neuralgia.  
The use of steroids in conjunction with an antiviral for uncomplicated herpes zoster is 
controversial. Steroids were found to accelerate the resolution of acute neuritis and provide 
a clear improvement in quality-of-life measures in comparison to those patients treated with 
antivirals alone. The use of oral steroids had no effect on the development or duration of 
postherpetic neuralgia. The optimal duration of steroid therapy is not known. If prescribed, 
it seems reasonable for steroids to be used concurrently with antiviral therapy. The duration 
of steroid use should not extend beyond the period of antiviral therapy. Steroids should not 
be given alone (without antiviral therapy) , owing to concern about the promotion of viral 
replication (Van Wijck 2006).  
Intrathecal administration of corticosteroids has also been attempted. A trial involving a 
series of 4 intrathecal injections of methylprednisolone and lidocaine in patients with 
established postherpetic neuralgia demonstrated a significant and persistent reduction in 
pain among corticosteroid-treated patients when compared with untreated patients or those 
treated with intrathecal lidocaine alone. Kotani et al. published remarkable results after the 
intrathecal injection of methylprednisolone in patients with intractable PHN for at least 1 yr, 
which showed a 50% decrease in interleukin-8 concentrations, and this decrease correlated 
with the duration of neuralgia and with the extent of global pain relief (Kotani 2000).  
The use of oral or epidural corticosteroids in conjunction with antiviral therapy has been 
found to be beneficial in treating moderate-to-severe acute zoster, but to have no effect on 
the development or duration of postherpetic neuralgia (Wood1994; Whitley 1996).  
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3.4. Temporomandibular joint disorders 
Temporomandibular joint (TMJ) disorders are the main cause of chronic facial pain and a 
major cause of disability (Horten 1953).  
Several decades ago, Toller suggested that intra-articular corticosteroid injections were only 
useful in adult patients with TMJ disorders; a single intra-articular injection resulted in 
resolution of TMJ pain and other symptoms in 62% of adult patients, compared to only 17% 
of pediatric patients (Toller 1977).  
Intra-articular injection of steroids into the temporomandibular joint (TMJ) space is not a 
recent subject. Horten in 1953, was the first who reported this procedure which was based 
on the work of Hollander et al. in which they described the effect of intra-articular injection 
of hydrocortisone in various joint disorders. Since then, a number of papers have reported 
varying degrees of success (Wood1994; Hollander 1951).  
A variety of methods are currently used for intra-articular corticosteroid injection to the 
TMJ, each with the goal of minimizing the potential for tissue damage. Intra-articular 
corticosteroid formulations are often diluted with a local anesthetic prior to injection into the 
TMJ (Kopp 1981; Alstergren 1996).  
Numerous corticosteroid formulations are available for intra-articular injection, ranging 
from solutions of more soluble agents to suspensions of triamcinolone hexacetonide and 
other relatively insoluble steroids. Although the efficacy of various corticosteroids is 
presumed to differ, studies of this topic have been limited (Wise 2005; Gerwin 2006; Lavelle 
2007).  
Triamcinolone acetonide which has been used for intra-articular injection is very slowly 
absorbed from the injection sites. The dose ranges between 2 to 40 mg, depending upon the 
size of the joint injected (Hollander 1951; Silbermann1978). In cases of TMJ, the dose is 
usually 10 mg (Gray 1994). Triamcinolone acetonide is a safe drug, although anaphylactic 
shock following injection of triamcinolone acetonide has been reported. A repeat injection is 
occasionally used but the third injection should be used with caution as the expectation of 
further improvement decreases with successive injections (Larsson 1989).  
In recent studies of juvenile idiopathic arthritis, intra-articular corticosteroid (triamcinolone) 
injections improved or even completely eliminated TMJ pain in 77-88% of children for 
several months (Arabshahi 2005; Cahill 2007; Ringold 2008).  
In a controlled study of adults with TMJ arthritis, a single intra-articular injection of 
corticosteroid (methylprednisolone) diluted with lidocaine significantly reduced joint pain 
and other symptoms for 4-6 weeks. The pharmacologic effect of intra-articular 
methylprednisolone lasts 3-4 weeks, so these findings were consistent with the expected 
timeline of corticosteroid effect. No adverse events were reported (Alstergren 1996).  
However, the efficacy may vary depending on the specific cause of TMJ degeneration.  
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3.5. Temporal arteritis (TA) 
Temporal arteritis (TA) , also known as cranial arteritis or Giant Cell Arteritis (GCA) , was 
first clinically recognized in 1890 when Hutchinson described an 80-year-old man whose 
painful inflamed temporal arteries precluded his wearing a hat (Hutchinson 1890). In 1932, 
Horton et al. correlated the histopathologic features with the clinical features and applied 
the name arteritis temporalis. Other names include arteritis cranialis, Horton disease, 
granulomatous arteritis, and arteritis of the aged (Horton 1932).  
There is universal agreement that glucocorticosteroids are the mainstay of treatment for 
GCA and should be initiated immediately and aggressively, with the goal of suppressing 
inflammation and preventing visual loss and ischemic stroke (Hayreh 2003; Rahman; 
Pipitone 2005).  
Oral prednisone is first-line acute therapy for GCA. Although no consensus exists for initial 
dose of prednisone, the vast majority of patients respond to a dose of 1 mg/kg/d, or between 
40 and 60 mg/d (Salvarani 2002; Weyand 2003). The dose of prednisone is lowered after 2–4 
weeks, and slowly tapered over 9–12 months (Chan 2001).  
Higher doses of 80 to 100 mg/d are suggested for patients with visual or neurological 
symptoms of GCA. IV pulse methylprednisolone has been proposed as an induction 
therapy, particularly in cases where vision is at risk (Rahman; Rahman 2005).  
4. Medical emergencies in dental practice 
4.1. Adrenal crisis prophylaxis 
Patients with a history compatible with adrenal suppression and presenting with features of 
adrenal crisis should be treated urgently.  
Acute adrenal crisis, with insufficiency of mineralocorticoids and glucocorticoids, is a 
medical emergency. The patient presents with abdominal pain, weakness, hypotension, 
dehydration, nausea and vomiting. Laboratory findings may include decreased sodium 
(hyponatraemia), elevated potassium (hyperkalaemia) , decreased blood glucose 
(hypoglycemia), acidosis and uraemia. Few patients have all these findings, with 
hypotension and nausea being most common.  
Patients with secondary Addison's most typical presentation is of hypotension, and 
hyponatraemia without volume depletion. Additional symptoms may include fatigue, 
weakness, arthralgia, nausea, and orthostatic dizziness associated with hypotension.  
Patients taking exogenous glucocorticoids. Exogenous glucocorticoids can cause adrenal gland 
suppression and resultant atrophy. With atrophy of the adrenal glands there is a decreased 
glucocorticoid response to stress, and this may precipitate an adrenal crisis (Edwards 1995).  
4.1.1. Management 
i. Intravenous fluids, in the form of 5% dextrose in normal saline, should be given to 
address the volume depletion that is often present.  
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ii. Primary adrenal insufficiency: start on 20–25 mg hydrocortisone per 24 h 
iii. Secondary adrenal insufficiency: 15–20 mg hydrocortisone per 24 h; if borderline fail in 
cosyntropin test consider 10 mg or stress dose cover only 
iv. Hydrocortisone should be given intravenously initially. If improvement has occurred 
within 24 hours, which is common, the hydrocortisone dose can be decreased. This can 
be changed to an oral formulation whenever the patient is stable. The dose can be 
decreased by one third to one half the dose daily until a maintenance dose of 20 mg in 
the morning and 10 mg in the afternoon or at night is attained. Some patients may need 
only a dose of 20 mg/day total (i.e., 20 mg every morning, or 15 mg in the morning and 
5 mg in the afternoon or at night).  
v. A search for the condition that precipitated the crisis, such as infection, should be 
undertaken. Treatment of the underlying cause should be instituted.  
vi. Patients will not need mineralocorticoid replacement, because the renin-angiotensin-
aldosterone axis is intact (Arlt 2009).  
4.2. Anaphylaxis shock 
Anaphylaxis is the quintessential disease of emergency medicine. The term anaphylaxis 
literally meaning “against protection” was introduced by Richet and Portier in 1902 (Brown 
1995).  
It is a potentially fatal illness with rapid onset that can affect young, healthy people. It must 
be diagnosed clinically, and is potentially curable if treated immediately (Golden 2007).  
A systematic review of the literature has failed to demonstrate the effectiveness of any of 
these medications in the treatment of anaphylaxis (Ewan 2010).  
Steroids are unlikely to be helpful in the treatment of acute anaphylaxis. They have a 
delayed onset of 4 to 6 hours. Steroids are thought to play a role in preventing rebound 
anaphylaxis; however, this has never been proven (Review Anaphylaxis in the emergency 
department 2008).  
As with the antihistamines, despite their many theoretical benefits on mediator release and 
tissue responsiveness, there are no placebo-controlled trials to confirm the effectiveness of 
steroids in anaphylaxis.  
Most clinicians however give prednisone 1 mg/kg up to 50 mg orally or hydrocortisone 1. 5-
3 mg/kg IV particularly in patients with airway involvement and bronchospasm, based 
empirically on their important role in asthma (Soar 2008).  
It is unclear if steroids prevent a biphasic reaction with recrudescence of symptoms 
following recovery, as supporting data are unconvincing (Lieberman 2005).  
Steroids are of course fundamental to the management of recurrent idiopathic anaphylaxis 
(Ring 2002; Greenberger 2007).  
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5. Emergency drugs in general dental practice 
5.1. Intracanal corticosteroid in root canal therapy 
The application of antiinflammatory agents on exposed pulp tissue in an attempt to prevent 
or minimize inflammatory reaction and to favor healing has been investigated for a long 
time. Corticosteroid can be used as a dressing agent for deep cavities and exposed pulp 
tissue in order to control the inflammatory pulp response and reduce postoperative pain. 
The therapeutic effect of a corticosteroid agent seems to depend upon its potency, 
concentration and ability to diffuse into connective tissue (Holland 1991; Gordon Marshall 
2002).  
The results of studies that employ corticosteroids as a cavity liner support that these 
medications are effective in reducing or preventing postoperative thermal sensitivity. 
Researchers have shown that application of corticosteroid/ antibiotic association for short 
period of time was effective to control inflammation in the pulp tissue without determining 
changes in the healing process (Santini 1983).  
Triamcinolone acetonide is a potent corticosteroid that could be used effectively to eliminate 
or at least reduce the severe inflammation that might occur secondary to endodontic 
treatment (Negm 2001).  
5.2. Perioperative corticosteroid use in dentoalveolar surgery 
Several authors have examined the effects of corticosteroids for prevention of pain and 
edema associated with oral surgery. Dental surgeons are often advised to use corticosteroids 
during and after third molar removal and other dentoalveolar surgery to reduce 
postsurgical edema. The most commonly used forms of corticosteroids in dentoalveolar 
surgery include dexamethasone (oral), dexamethasone sodium phosphate and 
dexamethasone acetate, and methylprednisolone acetate and methyl prednisolone sodium 
succinate. Dexamethasone has a longer duration of action than methlyprednisolone and is 
considered more potent (Alexander 2000).  
Methylprednisolone has been used in a number of studies. Methylprednisolone is usually 
administered via the intramuscular or intravenous route though the possibility of topical 
(intraalveolar) application has been described, with a reduction in morbidity and possible 
side effects. This drug is five times more potent than cortisol, with scant associated saline 
retention and an intermediate duration of action (12-36 hours) (Micó-Llorens 2006; Leone 
2007; Vegas-Bustamante 2008).  
Based on the literature review, interim recommendations for the use of corticosteroids are 
proposed, including dosages and regimens that appear rational for oral, intramuscular, or 
intravenous corticosteroid administration before and after extractions and other 
dentoalveolar surgery. These largely empiric recommendations might require adjustment 
when evidence-based data become available in future studies 
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6. Adverse effects of steroids 
Corticosteroids are chemical compounds of hormonal nature derived from cholesterol. Their 
biological power and actions depend on their chemical structure. Due to the remarkable 
anti-inflammatory and immunoregulatory effects of the corticosteroids, they have been 
employed as first step in the management of different diseases, and sometimes they are the 
only possible drug to use in daily medical practice. Despite their clinical efficacy, they can 
induce multiple severe adverse effects.  
Adverse effects of corticosteroids may be due to local effects on the skin or mucosa at the 
site of or to systemic effects following absorption of the oral drugs. Systemic side effects are 
rarer than local side effects.  
6.1. Systemic adverse effects 
Systemic side effects occur because the steroids contained in the corticosteroid become 
absorbed into the blood stream and begin to affect other parts of the body, such as the 
adrenal gland (a gland that produces many of the body’s natural steroids).  
Systemic side effects can include (Lozada-Nur 1991; Bircher 1996): 
 Hypothalamic-Pituitaryadrenal Axis and Secondary Adrenal  
 Insufficiency 
 Weight gain 
 Osteoporosis 
 Diabetes 
 High Blood Pressure (hypertension)  
 Psychological Effects 
 Indigestion or Heartburn 
 Cushing’s Syndrome  
 Moon Face 
 Bone Damage  
 Decreased Growth in Children  
 Skin can become thin, easily bruised and slow to heal 
 Avascular Necrosis (a painful bone condition)  
 Glaucoma 
6.2. Local adverse effects 
While topical steroids have tremendous benefit in reducing inflammation, they also have 
significant side effects. Most of these side effects are seen with long-term use, but some may 
be noticed within days of starting therapy. The risk of side effects from topical 
corticosteroids is related to drug potency, duration of therapy, frequency of application and 
anatomical area. Local side effects can include (Key2003; Baid 2006): 
 Tachyphylaxis 
 Burning Mouth 
 Hypogeusia 
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 Oral Hairy Leukoplakia  
 Hypersensitive Reactions to the Drug 
 Topical Steroid Allergy 
 Skin Atrophy 
 Striae - Stretch Marks 
 Acne form/Rosacea like eruptions 
 Candidosis 
 Delayed Healing 
 Fine Hair Growth 
6.2.1. Special Considerations 
Because corticosteroids cause the adrenal glands to slow or stop the production of cortisol, 
they cannot be discontinued abruptly. It takes some time for the adrenal glands to begin 
producing cortisol again. Gradually tapering the dose of corticosteroids allows the body to 
begin producing its own supply of cortisol again.  
 Undertake weight bearing exercise (such as brisk walking)  
 Stop smoking 
 Avoid excess alcohol intake 
 Contraindications for acute HSV Infection 
 Creams are less effective in the mouth than ointments, and the ointment form is preferred.  
7. Guidelines on the management of dental patients on corticosteroid 
therapy in community dental clinics 
General dental procedures for patients receiving long-term steroid medication do not 
warrant supplementation with additional glucocorticoids.  
The aims of these guidelines are to assist and support Dentists and Dental therapists when 
providing dental treatment to patients who are currently receiving, or who have received 
Corticosteroid therapy in the past twelve months.  
7.1. For routine conservative dentistry or minor oral surgery (to include one 
simple extraction) under local anaesthesia 
Although Opinions Conflict On Whether Any Significant Suppression Of Adrenal Function 
Occurs In Patients Taking Low Doses Of Steroids (Under 7. 5 Mg Prednisolone) Available 
Evidence Suggests That Supplementation Is Unnecessary For Local Anaesthetic Procedures.  
7.2. For minor surgery under general anesthesia for patients undergoing general 
anesthesia for minor surgery 
100 Mg Hydrocortisone Intramuscularly Should Be Administered And The Usual 
Glucocorticoid Medications Maintained.  
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7.3. For major surgery 
100 Mg Hydrocortisone Delivered As A Bolus Pre-Operatively Followed By 50 Mg 8-Hourly 
For 48 Hours Is Adequate.  
7.4. American Society of Anaesthesiologists (ASA) Physical Classification Status 
1. A normal healthy patient 
2. A patient with mild systemic disease 
3. A patient with severe systemic disease 
4. A moribund patient who is not expected to survive without surgery 
5. A declared brain-dead patient whose organs are being removed for donor purposes.  
Patients with ASA score 1 and 2 who are currently on or who have been on corticosteroids 
in the last year.  
Patients with ASA score 3 and 4 who are currently on or who have been on corticosteroids 
in the last year.  
Any patient that does not fit the above criteria or if the clinician is in any doubt then the 
patient should not be treated in the primary care setting and should be referred (Gibson 2004).  
Author details 
Masoumeh Mehdipour and Ali Taghavi Zenouz 
Oral and Maxillofacial Medicine Department, Tabriz Faculty of Dentistry,  
Tabriz University of Medical Sciences, Iran 
8. References 
Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus. (2004). Criteria for Steroid-
Sparing Ability of Interventions in Systemic Lupus Erythematosus: Report of a 
Consensus Meeting, Arthritis & Rheum, 50:3427 
Adour KK, Wingerd J, Bell DN, Manhing JJ, Hurley JP. (1972). Prednisone treatment for 
idiopathic facial paralysis (Bell’s palsy). N Engl J Med. 287: 1268–72.  
Alexander RE, Throndson RR (2000). A review Of Perioperative Corticosteroid use In 
Dentoalveolar Surgery, Oral Surg Oral Med Oral Path . 90:406-15 
Alstergren P, Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. (1996). The 
effect on joint fluid concentration of neuropeptide Y by intra-articular injection of 
glucocorticoid in temporomandibular joint arthritis. Acta Odontol Scand. 54:1–7.  
Arabshahi B, Dewitt EM, Cahill AM, Kaye RD, Baskin KM, Towbin RB, Cron RQ. (2005). 
Utility of corticosteroid injection for temporomandibular arthritis in children with 
juvenile idiopathic arthritis. Arthritis Rheum. 52:3563–3569.  
Arlt W. (2009). The Approach to the Adult with Newly Diagnosed Adrenal Insufficiency J 
Clin Endocrinol Metab. 94 (4) :1059–1067 
 
State of the Art of Therapeutic Endocrinology 112 
Bagan J, Lo Muzio L, Scully C. (2005). Mucosal disease series. Number III. Mucous 
membrane pemphigoid. Oral Dis. 11:197-218.  
Baid SK, Nieman LK. (2006). Therapeutic doses of glucocorticoids: implications for oral 
medicine. Oral Dis. 12:436-42.  
Bircher AJ, Pelloni F, Langauer Messmer S, Müller D. (1996). Delayed hypersensitivity 
reactions to corticosteroids applied to mucous membranes. Br J Dermatol. 35:310-3.  
Borradori L, Bernard P. (2004). Vesiculobullous diseases: pemphoid group.  eds. 
Dermatology. Philadelphia, PA: Mosby/Elsevier; 463-- 470  
Brown AFT. (1995). Anaphylactic shock: Mechanisms and treatment. J Acc Emerg Med. 
12:89-100.  
Bruce A , Rogers RS III. (2007). New and old therapeutics for oral ulcerations. Arch 
Dermatol. 143: 519–23 
Bystryn JC. Steinmann NM. (1996). The adjuvant therapy of pemphigus. Arch Dermatol. 
132:203-12.  
Cahill AM, Baskin KM, Kaye RD, Arabshahi B, Cron RQ, Dewitt EM et al. (2007). CT-guided 
percutaneous steroid injection for management of inflammatory arthropathy of the 
temporomandibular joint in children. AJR Am J Roentgenol. 188:182–186 
Camisa C, Warner M. (1998). Treatment of pemphigus. Dermatol Nurs . 10 (2) :115-31.  
Carbone M, Carrozzo M, Conrotto D, Garzino Demo P, Broccoletti R, Gandolfo S . (1997). 
Topical treatment of atrophic-erosive oral lichen planus with clobetasol in bioadhesive 
gel as well as chlorhexidine and miconazole in oral gel. Minerva stomatologica. 46 (7-
8):423-8.  
Carbone M, Conrotto D, Carrozzo M, Broccoletti R, Gandolfo S, Scully C. (1999). Topical 
corticosteroids in association with miconazole and chlorhexidine in the long-term 
managementof atrophic-erosive oral lichen planus: a placebo-controlledand 
comparative study between clobetasol and fluocinonide. Oral Dis . 5:44-9.  
Cawson RA. (1968). Treatment of Oral Lichen Planus with Betamethasone. Br. Med. J. 2:86-
89.  
Chainani-Wu N, Silverman S Jr, Lozada-Nur F, Mayer P, Watson JJ. (2001). Oral lichen 
planus: patient profile, disease progression and treatment responses. J Am Dent Assoc. 
132:901-9.  
Chan CC, Paine M, O'Day J. (2001). "Steroid management in giant cell arteritis". Br J 
Ophthalmol 85 (9) :1061–4.  
Chrousos GP. (2004). Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG, 
ed. Basic & Clinical Pharmacology. 9th ed. New York, NY: Lange Medical 
Books/McGraw-Hill. 641–660.  
Cotell S, Robinson ND, Chan LS. (2000). Autoimmune blistering skin diseases . Am J Emerg 
Med . 18:288-99.  
Dumas V, Roujeau JC, Wolkenstein P, Revuz J, Cosnes A. (1999). The treatment of mild 
pemphigus vulgaris and pemphigus foliaceus with a topical corticosteroid. Br J 
Dermatol. 140 (6) :1127-9.  
Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. (2007). 
Recommendations for the management of herpes zoster. Clin Infect Dis. 44 Suppl 1:S1-
26.  
 
Role of Corticosteroids in Oral Lesions 113 
Edwards CR, Baird JD, Frier B M, Shepherd J, Toft AD. (1995). Endocrine and metabolic 
diseases, including diabetes mellitus. In Edwards C R, Bouchier I A, Haslett C, Chilvers 
E R (eds) Davidson's principles and practice of medicine. 17th ed. pp 706-719. 
Edinburgh: ChurchillLivingstone 
Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation and Management. J. 
C. D. 68:494-9.  
Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. (2005). Oral lichen planus: 
Clinical features and management. Oral Dis. 11:338-49.  
Engström M, Berg T, Stjernquist-Desatnik A, Axelsson S, Pitkäranta A, Hultcrantz M et al. 
(2008). Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, 
placebo-controlled, multicentre trial. Lancet Neurol. 7 (11) :993-1000.  
Ewan PW, DuguéP, Mirakian R, Dixon TA, Harper JN, Nasser SM. (2010). BSACI guidelines 
for the investigation of suspected anaphylaxis during general anaesthesia. Clin Exp 
Allergy. 40 (1) :15.  
Fassmann A, Dvo. akova N, Izakoviaova Holla L, Vanuk J, Wotke J. (2003). Manifestation of 
Pemphigus Vulgaris in the orofacial region. Case report. Scripta Medica (brno). 76:55–
62.  
Fellner MJ, Sapadin AN. (2001). Current therapy of pemphigus vulgaris. Mt Sinai J Med . 68 
(4-5) :268–78.  
Femiano F, Gombos F, Scully C. (2002). Pemphigus vulgaris with oral involvement: 
Evaluation of two different systemic corticosteroid therapeutic protocols. J 
EurAcadDermatolVenereol . 16 (4) :353-6.  
Fernandes NC, Perez M. (2001). Treatment of pemphigus vulgaris and pemphigus foliaceus: 
experience with 71 patients over a 20 year period. Revista do Instituto de Medicina 
Tropical de Sao Paulo . 43 (1) , 33-36.  
Field EA, Allan RB. (2003). Review article: oral ulceration – aetiopathogenesis, clinical 
diagnosisand management in the gastrointestinal clinic. Blackwell Publishing Ltd, 
Aliment 
Fitzpatrick TB, Freedberg IM, Eisen AZ, Wolff K, Austen KF,Goldsmith LA, et al. (2008). 
Fitzpatrick's dermatology in general medicine (7th ed.). New York: McGraw-Hill.  
Forman R, Koren G, Shear NH. (2002). Erythema mutliforme, Stevens-Johnson syndrome 
and toxic epidermal necrolysis in children: a review of 10 years’ experience. Drug Saf. 
25 (13) :965–972.  
French L, Prins C. (2008). Erythema multiforme, Stevens-Johnson syndrome and toxic 
epidermal necrolysis. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. 
Philadelphia PA: Elsevier. 287–300.  
Funauchi M, Ikoma S, Imada A, Kanamaru A. (1997). Combination of immune adsorption 
therapy and high dose methyl prednisolone in patients with lupus nephritis; possible 
indications in patients with early stage. J Clin Lab Immunol. 49: 47 – 57.  
Gerwin N, Hops C, Lucke A. (2006). Intraarticular drug delivery in osteoarthritis. Advanced 
Drug Delivery Reviews. 58:226–242.  
Gibson N, Ferguson JW. (2004). Steroid cover for dental patients on long-term steroid 
medication: proposed clinical guidelines based upon a critical review of the literature 
British Dental Journal . 197 (11) : 681–685 
 
State of the Art of Therapeutic Endocrinology 114 
Gilden DH. (2004). Clinical Practice. Bell’s palsy. The New England Journal of Medicine. 351 
(13) :1323–31.  
Golden DB. (2007). What is anaphylaxis? Curr Opin Allergy Clin Immunol. 7 (4) :331–6 
Greenberger PA. (2007). Idiopathic anaphylaxis. Immunol Allergy Clin N Am 27:273-93.  
Gonzalez-Moles MA, Morales P, Rodriguez-Archilla A, Isabel IR, Gonzalez-Moles S. (2002). 
Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous 
solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 93:264-70.  
Gordon Marshall J. (2002). Consideration of steroids for endodontic pain Endodontic Topics 
. 3, 41–51 
Gray RJM, Davies SJ, Quayle AA. (1994). A clinical approach to temporomandibular 
disorders: Treatment planning, general guidelines and case histories. Br Dent J. 171: 
171-178.  
Greenspan JS, Yeoman CM, Harding SM. (1978). Oral Lichen Planus: A Double-Blind 
Comparison of Treatment with Betamethasone Valerate Aerosol and Pellets. Br. Dent. J. 
144:83-84.  
Grogan PM, Gronseth GS. (2001). Practice parameter: steroids, acyclovir, and surgery for 
Bell's palsy (an evidence-based review) : report of the Quality Standards Subcommittee 
of the American Academy of Neurology. Neurology. 56: 830-6.  
Grover VK, Babu R, Bedi SPS. (2007). Steroid Therapy – Current Indications in Practice. 
Indian Journal of Anaesthesia. 51 (5) : 389-393 
Harman KE, Albert S, Black MM. (2003). Guidelines for the managementof pemphigus 
vulgaris. Br J Dermatol. 149 (5) : 926-37.  
Hashimoto T. (2008). Treatment strategies for pemphigus vulgaris in Japan. Expert 
OpinPharmacother. 9:1519-30.  
Hato N, Yamada H, Kohno H, Matsumoto S, Honda N, Gyo K et al. (2007). Valacyclovir and 
prednisolone treatment for Bell s palsy: A multicenter, randomized, placebo-controlled 
study. Otology andNeurotology. 28:408–13.  
Hayreh SS, Zimmerman B. (2003). Management of giant cell arteritis. Our 27-year clinical 
study: new light on old controversies. Ophthalmologica. 217:239–259 
Hegarty AM, Hodgson TA, Lewsey JD, Porter SR. (2002). Fluticasone propionate spray and 
betamethasone sodium phosphate mouthrinse: a randomized crossover study for the 
treatment of symptomatic oral lichen planus. J AmAcad Dermatol. 47: 271 – 279.  
Hench PS, Kendall EC, Slocumb CH, Polley HF. (1949). The effect of a hormone of the a 
drenal cortex (17-hydroxy-11-dehydrocorticosterone:compound E) and of pituitary 
adrenocorticotropic hormone on rheumatic arthritis. Proc Staff Meet Mayo Clin. 24:181 
Hill G, Chauvenet AR, Lovato J, McLean TW. (2005). Recent steroid therapy increases 
severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics 
. 116 (4) :523–9.  
Hiroshige K, Ikeda M, Hondo R. (2002). Detection of varicella zoster virus DNA in tear fluid 
and saliva of patients with Ramsay Hunt syndrome. Otol Neurotol. 23 (4) :602–7.  
Hollander JL, Brown EM, Jessar RA, Brown CY. (1951). Hydrocortisone and Cortisone 
injected into arthritic joints: Comparative effect of and use of hydrocortisone as a local 
antiarthritic agent. JAMA. 147: 1629-1236.  
Holland R, Okabe JA, Souza V, Saliba O. (1991). Diffusion of corticosteroid antibiotic 
solutions through human dentine. Rev Odontol UNESP. 20: 17-23.  
 
Role of Corticosteroids in Oral Lesions 115 
Horten CP. (1953). The Treatment of Arthritic Temporomandibular Joints by Intra-articular 
Injection of Hydrocortisone. Oral Surg. 6: 826-829.  
Horton B, Magath T, Brown G. (1932). An undescribed form of arteritis of the temporal 
vessels. Proc Staff Mtg MayoClin. 7:700-701.  
Huff JC. (1992). Erythema multiforme and latent herpes simplex infection. Semin Dermatol. 
11:207–10.  
Hutchinson J. (1890). Diseases of the arteries. On a peculiar form of thrombotic arteritis of 
the aged which is sometimes productive of gangrene. ArchSurg. 1:323-9.  
Hyvernat H, Roger PM, Pereira C, Saint-Paul MC, Vandenbos F, Bernardin G. (2005). Fatal 
varicella hepatitis in an asthmatic adult after short-term corticosteroid treatment. Eur J 
Intern Med. 16 (5) :361–2.  
Ippolito A , Petri M. (2008). An Update on Mortality in Systemic Lupus Erythematosus, Clin 
Exp Rheumatol, 26 (5 Suppl 51) :S72-9.  
Jacobson C, Cornell R, Savin R. (1986). A comparison of clobetasol propionate 0. 05% 
ointment and optimized betamethasone dipropionate 0. 05% ointment in the treatment 
of psoriasis. Cutis. 37:213-20.  
Johnson RW. (2002). Consequences and management of pain in herpes zoster. J Infect Dis. 
186 (suppl 1) :S83–S90 
Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. (2002). A comparison of 
oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 346 
(5) : 321-7.  
Joly P, Benichou J, Lok C, Hellot MF, Saiag P, Tancrede-Bohin E et al. (2005). Prediction of 
survival for patients with bullous pemphigoid. Arch Dermatol. 141: 691-698.  
Joly P, Roujeau JC, Benichou J, Delaporte E, D'Incan M, Dreno B et al. (2009). A comparison 
of two regimens of topical corticosteroids in the treatment of patients with bullous 
pemphigoid: A multicenter randomized study. J Invest Dermatol. 129 (7) : 1681-7.  
Kakourou T, Klontza D, Soteropoulou F, Kattamis C. (1997). Corticosteroid treatment of 
erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr. 
156:90–93.  
Kardaun S, Jonkman M. (2007). Dexamethasone Pulse Therapy for Stevens-Johnson 
syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 87:144–148.  
Kasperkiewicz M, Enno Schmidt E. (2009). Current Treatment of Autoimmune Blistering 
Diseases. Current Drug Discovery Technologies, , 6, 270-280 
Kelly DJ, Ahmad M, Brull SJ. (2001). Preemptive analgesia I: physiological pathways and 
pharmacological modalities. Can J Anaesth.:1000–10 
Khare V. (2011). Discoid Lupus Erythematosus - A Case Report JIDA, Vol. 5, No. 1 
Key SJ, Hodder SC, Davies R, Thomas DW, Thompson S. (2003). Perioperative corticosteroid 
supplementation and dento-alveolar surgery. Dent Update. 30:316-20.  
Kinishi M, Amatsu M, Mohri M, Saito M, Hasegawa T, Hasegawa S. (2001). Acyclovir 
improves recovery rate of facial nerve palsy in Ramsay Hunt syndrome. Auris Nasus 
Larynx. 28 (3) :223–6. 9 
Knudson RM, Kalaaji AN, Bruce AJ. . (2010). The management of mucous membrane 
pemphigoid and pemphigus. Dermatol Ther. 23:268-80.  
Kopp S, Wenneberg B.(1981). Effects of occlusal treatment and intra-articular injections on 
temporomandibular pain and dysfunction. ActaOdontol Scand. 39:87–96.  
 
State of the Art of Therapeutic Endocrinology 116 
Kotani N, Kushikata T, Hashimoto H, Kimura F, Muraoka M, Yodono M. et al. 
(2000).Intrathecal methyl prednisolone for intractable postherpetic neuralgia. N Engl J 
Med.; 343 (21):1514-9.  
Lai DR, Chen HR. (1995). Clinical Evaluation of Different Treatment Methods for Oral 
Submucous Fibrosis. A 10-year experience with 150 cases, JOPM. 24, 402-614.  
Lamoreux MR, Sternbach MR, Hsu WT. (2006). Erythema multiforme. Am Fam Physician. 
74:1883–1888.  
Larsson L. (1989). Anaphylactic shock after administration of triamcinolone acetonide in a 
35 year old female. Scand J Rheamtol. 18: 441-444.  
Lavelle W, Lavelle ED, Lavelle L. (2007). Intra-articular injections. Med Clin North Am. 
91:241–250.  
Leone M, Richard O, Antonini F, Rousseau S, Chabaane W, Guyot L, et al. (2007). 
Comparison of methylprednisolone and ketoprofen after multiple third molar 
extraction: a randomized controlled study. Oral Surg Oral Med Oral Pathol Oral Radiol 
Endod. 103:e7-9.  
Lever WF, Schaumburg-Lever G. (1984). Treatment of pemphigus vulgaris. Results obtained 
in 84 patients between 1961 and 1982. Arch Dermato. 120 (1) :44–7.  
Levin C, Maibach HI. (2002) :Topical corticosteroid-induced adrenocortical insufficiency: 
clinical implications. Am J Clin Dermatol. 3:141–7.  
Lieberman P. (2005). Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol . 
95:217-26.  
Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. (2005). Current 
controversies in oral lichen planus: report of an international consensus meeting – Part 
1. Viral infections and aetiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol 
Endod 100: 40-51.  
Lo Muzio L, della Valle A, Mignogna MD, Pannone G, Bucci P, Bucci E, et al. (2001). The 
treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol 
propionate in three preparations: a clinical and pilot study on 54 patients. J OralPathol 
Med . 30:611-7.  
Lozada –Nur F, Silverman S Jr. (1980). Topically applied fluocinonide in an adhesive base in 
the treatment of oral vesiculoerosive diseases. Arch Dermatol . 116:898-901.  
Lozada-Nur F, Huang MZ, Zhou GA. (1991). Open preliminary clinical trial of clobetasol 
propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive 
diseases. Oral Surg Oral Med Oral Pathol . 71:283-7.  
Lozada-Nur F, Miranda C, Maliksi R. (1994). Double-blind clinical trial of 0. 05% clobetasol 
propionate ointment in orobase and 0. 05% fluocinonide ointment in orobase in the 
treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral 
Pathol. 77: 598–604.  
MacPhee IT, Sircus W, Farmer ED, Harkness RA, Cowley GC. (1968). Use of steroids in 
treatment of aphthous ulceration. Br Med J. 2:147-9.  
Mamelak AJ, Eid MP, Cohen BA, Anhalt GJ. (2007). Rimximab therapy in severe juvenile 
pemphigus vulgaffs. Cutis. 80 (4) , 335–340.  
Martinez AE, Atherton DJ. (2000). High-dose systemic corticosteroids can arrest recurrences 
of severe mucocutaneous erythema multiforme. Pediatr Dermatol. 17 (2) :87–90.  
 
Role of Corticosteroids in Oral Lesions 117 
Mehdipour M, Taghavi Zenouz A, Bahramian A, Yazdani J, Poura- libaba F,Sadr K. (2010). 
Comparison of the Effect of Mouthwashes with and without Zinc and Fluocinolone on 
the Healing Process of Erosive Oral Lichen Planus. JODDD. 4 (1) :25-28 
Mentink LF, Mackenzie MW, Tóth GG, Laseur M, Lambert FP, Veeger NJ, et al. (2006). 
Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in 
pemphigus vulgaris: PEMPULS trial. Arch Dermatol. 142 (5) :570-6.  
Merchant HW, Gangarosa LP, Glassman AB, Sobel RE. (1978). Betamethasone-17-benzoate 
in the treatment of recurrent aphthous ulcers. Oral Surg. 45:870-5.  
Micó-Llorens JM, Satorres-Nieto M, Gargallo-Albiol J, Arnabat-Domínguez J, Berini-Aytés L, 
Gay-Escoda C. (2006). Efficacy of methylprednisolone in controlling complications after 
impacted lower third molar surgical extraction. Eur J Clin Pharmacol. 62:693-8.  
Mondino BJ, Brown SI. (1981). Ocular cicatricial pemphigoid. Ophthalmology. 88:95-100.  
Murakami S, Hato N, Horiuchi J, Honda N, Gyo K, Yanagihara N. (1997). Treatment of 
Ramsay Hunt syndrome with acyclovir-prednisone: significance of early diagnosis and 
treatment. Ann Neurol. 41:353-7.  
Mutasim DF, Cincinatti. (2004). Management of Autoimmune Bullous Disease: 
Pharmacology and Therapeutics, J. Am. Acad. Dermatol. 51:859-77.  
Natah SS, Konttinen YT. (2004). Recurrent Aphthous Ulcers Today: a review of the growing 
knowledge, IJOMS. 33:221-34.  
Negm M M. (2001). Intracanal use of a Corticosteroid – antibiotic compound for the 
management of post treatment endodontic pain. Triplo. 92:435-9.  
Oztas P, Onder M, Ilter N, Oztas MO. (2003). Childhood lichen planus with nail 
involvement: a case. Turkish J Pediatrics. 45:251-253.  
Panjwani S. (2009). Early Diagnosis and Treatment of Discoid Lupus Erythematosus. J Am 
Board Fam Med. . 22 (2) :206-213.  
Pavan-Langston D. (2008). Herpes zoster antivirals and pain management. Ophthalmology. 
115:S13–S20 
Pedersen A, Klausen B. (1984). Glucocorticosteroids and Oral Medicine, Oral Pathology & 
Medicine J. 13:1-15 
Pimlott SJ, Walker DM. (1983). A controlled clinical trial of the efficacy of topically applied 
fluocinonide in the treatment of recurrent aphthous ulceration. Br Dent J. 154:174-7 
Pipitone N, Boiardi L, Salvarini C. (2005). Are steroids alone sufficient for the treatment of 
giant cell arteritis? Best Pract Res Clin Rheumatol. 19:277–292 
Prajapati V, Mydlarski PR. (2008). Advances in pemphigus therapy. Skin Therapy Lett. 13:4-7.  
Rabiyi M, Sahebjamee M. (2003). Effect of aqueous triamcinolone actonide 0. 2% suspension 
in treatment oforal lichen planus. Journal Medical Faculty GuilanUniversity of Medical 
Sciences. 12: 6 – 14.  
Rahman W, Rahman FZ. (2005). Major review – giant cell (temporal) arteritis: an overview 
and update. Surv Ophthalmol. 50:415–428 
Ramsey MJ, Der Simonian R, Holtel MR, BurgessLPA. (2000). Corticosteroid treatment for 
idiopathic facialnerve paralysis: a meta-analysis. Laryngoscope. 110: 335–41.  
Ratnam KV, Phay KL, Tan CK. (1990). Pemphigus therapy with oral prednisolone regimens: 
A 5-year study. Int J Dermatol. 29 (5) :363-7.  
Rees TD, Binnie WH. (1996). Recurrent aphthous stomatitis. Dermatol Clin. 14:243-56.  
 
State of the Art of Therapeutic Endocrinology 118 
Reich RF, Kerpel SM. (1998). Differential Diagnosis and Treatment of Ulcerative, Erosive 
and Vesiculobullous Lesions of Oral Mucosa, Oral and Maxillofacial Surgery Clinics of 
North America. 10: 95-129.  
ReviewAnaphylaxis in the emergency department. (2008). a paediatric perspective. Curr 
Opin Allergy Clin Immunol. 8 (4) :321-9.  
Ring J, Darsow U. (2002). Idiopathic anaphylaxis. Curr Allergy Asthma Reports . 2:40-5.  
Robillard RB, Hilsinger RL Jr, Adour KK. (1986). Ramsay Hunt facial paralysis: clinical 
analyses of 185 patients. Otolaryngol Head Neck Surg. 1:292–7.  
Ringold S, Torgerson TR, Egbert MA, Wallace CA. (2008). Intraarticular corticosteroid 
injections of the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol. 
35:1157–1164.  
Roed-Petersen B, Roed-Petersen J. (1992). Occlusive treatment of atrophic and erosive oral 
lichen planus with clobetasol propionate 0. 05% ointment (Dermovat) [Danish]. 
Tandlaegernes Tidsskr. 1:4- 7.  
Ruocco E, Aurilia A, Ruocco V. (2001). Precautions and suggestions for pemphigus patients. 
Dermatology. 203 (3) :201–7.  
Salvarani C, Cantini F, Bolardi L, Hunder GG. (2002). Polymyalgia rheumatica and giant-cell 
arteritis. N Engl J Med. 347:261–271 
Santini A. (1983). Assessment of the pulpotomy technique in human first permanent 
mandibular molars. Br Dent J. 155: 151-4.  
Setterfield JF, Black MM , Challacombe SJ. (2000). The management of oral lichen planus. 
Clin Exp Dermatol. 25: 176–82.  
Schmader KE, Dworkin RH. (2008). Natural history and treatment of herpes zoster. J Pain. 
9:S3–S9 
Scully C, Bagan J. (2008). Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac 
Surg. 46:90–95.  
Scully C, Lo Muzio L. (2008). Oral mucosal diseases: mucous membrane pemphigoid. Br J 
Oral Maxillofac Surg. 46:358-66.  
Shin HT, Chang MW. (2001). Drug eruptions in children. Curr Probl Pediatr. 31:207–34.  
Shafshak TS, Essa AY, Bakey FA. (1994). The possible contributing factors for the success of 
steroid therapy in Bell's palsy: a clinical and electrophysiological study. J Laryngol Otol. 
108: 940-3.  
Ship JA. (1996). Recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol 
Endod. 81:141-7.  
Silbermann M, Moredohvich D, Toister Z, Azaria N. (1978). Mechanisms involved in 
mandibular condylopathy secondary to intra-articular injections of glucocorticoids. J 
Oral Surg. 36: 112-117.  
Silverman S Jr, Gorsky M, Lozada-Nur F, Giannotti K. (1991). A prospective study of 
findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod. 72:665-70 
Sirois D, Leigh JE, Sollecito TP. (2000). Oral pemphigus vulgaris preceding cutaneous 
lesions: recognition and diagnosis. J Am Dent Assoc. 131, 1156-1160.  
Soar J, Pumphrey R, Cant A. (2008). Emergency treatment of anaphylactic reactions. 
Guidelines for health care providers. Resuscitation . 77:157-69 
 
Role of Corticosteroids in Oral Lesions 119 
Sullivan FM, Swan IR, Donnan PT, Morrison JM, Smith BH, McKinstry B, et al. (2007). Early 
treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med. 357 (16) :1598-
607.  
Taverner D. (1954). Cortisone treatment of Bell’s palsy. Lancet. ii:1052–4.  
Thompson AC, Nolan A, Lamey J. (1989). Minor aphthous oral ulceration: a double-blind 
cross-over study of beclomethasone dipropionate aerosol spray. Scott Med J. 34:531 
Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. (1992). Relative efficacy of 
fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral 
lichen planus.  
Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C. (2003). Clinical 
evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-
year follow-up. J Oral Pathol Med. 32: 315 – 322.  
Thost A. (1911). Der chronische schleimhaut-pemphigus der oberen luftwege. Arch Laryng 
Rhinol. 25:459-78.  
Toller PA. (1977). Use and misuse of intra-articular corticosteroids in treatment of 
temporomandibular joint pain. Proc Roy Soc Med. 70:461–463.  
Toth GG, Jonkman MF. (2001). Therapy of pemphigus . Clin Dermatol. 19 (6) :761–7 
Tht Yu J, Chong L, Kc Lee L. (2007). Pemphigoid, benign mucous membrane Hong Kong 
Med J. 13:157-60 
Tyldesley WR, Harding SM. (1977). Betamethasone Valerate Aerosol in the Treatment of 
Oral Lichen Planus. Br. J. Dermatol. 96:659-662.  
Uri N, Greenberg E, Kitzes-Cohen R, Doweck I. (2003). Acyclovir in the treatment of Ramsay 
Hunt syndrome. Otolaryngol Head Neck Surg. 129 (4) :379–81.  
Valença MM, Valença LP, Lima MC. (2001). Idiopathic facial paralysis (Bell’s palsy) : a study 
of 180 patients . Arquivos de Neuro-Psiquiatria. 59:733–9.  
Van de Steene V, Kuhweide R, Vlaminck S, Casselman J. (2004). Varicella zoster virus: 
beyond facial paralysis. Acta Otorhinolaryngol Belg. 58 (1) :61–6 
Van Wijck AJ, Opstelten W, Moons KG, van Essen GA, Stolker RJ, Kalkman CJ, et al. (2006). 
The PINE study of epidural steroids and local anaesthetics to prevent postherpetic 
neuralgia: a randomised controlled trial. Lancet; 367 (9506) :219-24.  
Vegas-Bustamante E, Micó-Llorens J, Gargallo-Albiol J, Satorres-Nieto M, Berini-Aytés L, 
Gay-Escoda C. (2008). Efficacy of methylprednisolone injected into the masseter muscle 
following the surgical extraction of impacted lower third molars. Int J Oral Maxillofac 
Surg. 37:260-3.  
Vincent SD, Lilly GE. (1992). Clinical, historic, and therapeutic features of aphthous 
stomatitis. Literature review and open clinical trial employing steroids. Oral Surg Oral 
Med Oral Pathol. 74:79-86.  
Vincent SD, Fotos PG, Baker KA, Williams TP. (1990). Oral Lichen Planus: The Clinical, 
Historical, and Therapeutic Features of 100 Cases. Oral Surg. Oral Med. Oral Pathol. 
70:165-171 .  
Volcheck GW. (2004). Clinical evaluation and management of drug hypersensitivity. 
Immunol Allergy Clin North Am. 24:357–71.  
Voute AB, Schulten EA, Langendijk PN, Kostense PJ, van der Waal I. (1993). Fluocinolone in 
an adhesive base for treatment of oral lichen planus. A double-blind, placebo controlled 
clinical study. Oral Surg Oral Med Oral Pathol. 75: 181 – 185.  
 
State of the Art of Therapeutic Endocrinology 120 
Werth VP. (1996). Treatment of pemphigus vulgaris with brief , high-dose intravenous 
glucocorticoids. Arch Dermatol. 132:1435 – 1439 
Westerhof W. (1989). Treatment of bullous pemphigoid with topical clobetasol propionate. J 
Am Acad Dermatol. 20: 458–61.  
Weyand CM, Goronzy JJ. (2003). Medium- and large-vessel vasculitis. N Engl J Med. 
349:160–169  
Whitley RJ, Weiss H, Gnann JW Jr, Tyring S, Mertz GJ, Pappas PG et al. (1996). Acyclovir 
with and without prednisone for the treatment of herpes zoster. A randomized, 
placebo-controlled trial. The National Institute of Allergy and Infectious Diseases 
Collaborative Antiviral Study Group. Ann Intern Med. 125 (5) :376-83.  
Williamson IG, Whelan TR. (1996). The clinical problem of Bell's palsy: is treatment with 
steroids effective? Br J Gen Pract. 46: 743-7.  
Wise C. (2005). In: Kelley's Textbook of Rheumatology. Seventh. Harris ED Jr, Budd RC, 
Genovese MC, Firestein GS, Sargent JS, Sledge CB, editors. Elsevier Saunders; 
Philadelphia:pp. 695–696.  
Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP. (2002). Summary of 
Recommendations for Management of Bullous Pemphigoid. Br J Dermatol. 147: 214-221 
Wolverton SE. (2007). Systemic corticosteroids. In: Wolverton SE, ed. Comprehensive 
Dermatologic Drug Therapy. 2nd ed. Philadelphia, PA: Saunders Elsevier. 127–161.  
Woo SB, Sonis ST. (1996). Recurrent aphthous ulcers: a review of diagnosis and treatment. J 
Am Dent Assoc. 127:1202-13.  
Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. (1994). A 
randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for 
treatment of acute herpes zoster. N Engl J Med. 330 (13) :896-900.  
Yazici H, Barnes CG. (1991). Practical treatment recommendations for pharmacotherapy of 
Behc¸et’s syndrome. Drugs. 42:796–804.  
Yeung AK, Goldman RD. (2005). Use of steroids for erythema multiforme in children. Can 
Fam Physician. 51 (11) :1481–1483.  
Zegarelli EV, Kutscher AH, Mehrhof A. (1969). Long-lasting lozenges with triamcinolone 
acetonide. Treatment of erosive lichen planus of oral mucosa. N Y State J Med . 69:2463-
4 
Zegarelli DJ. (1980). Topical and intralesional steroid therapy of oral lichen planus. N Y State 
Dent J. 46:432, 434-432, 436.  
Zegarelli DJ. (1983). Multimodality steroid therapy of erosive and ulcerative oral lichen 
planus. J Oral Med . 38:127-30.  
Zimmermann R, Faure M, Claudy A. (1999). Prospective study of treatment of bullous 
pemphigoid by a class I topical corticosteroid. Ann Dermatol Venereol. 126: 13–16.  
